Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $67,854.84 in Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) insider Jeffrey Alan Jones sold 4,982 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $13.62, for a total value of $67,854.84. Following the completion of the sale, the insider directly owned 164,550 shares of the company’s stock, valued at approximately $2,241,171. The trade was a 2.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jeffrey Alan Jones also recently made the following trade(s):

• On Tuesday, February 24th, Jeffrey Alan Jones sold 4,582 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $14.47, for a total transaction of $66,301.54.
• On Thursday, December 18th, Jeffrey Alan Jones sold 4,632 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $9.67, for a total value of $44,791.44.

Cullinan Therapeutics Trading Up 0.6%

CGEM opened at $14.36 on Thursday. The stock has a market cap of $848.39 million, a PE ratio of -4.34 and a beta of -0.09. The stock’s 50 day simple moving average is $11.50 and its 200-day simple moving average is $9.31. Cullinan Therapeutics, Inc. has a 1 year low of $5.68 and a 1 year high of $14.56.

Institutional Investors Weigh In On Cullinan Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd raised its stake in Cullinan Therapeutics by 62.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock worth $28,000 after buying an additional 1,036 shares during the last quarter. CWM LLC grew its stake in shares of Cullinan Therapeutics by 51.5% in the 4th quarter. CWM LLC now owns 3,876 shares of the company’s stock worth $40,000 after acquiring an additional 1,318 shares in the last quarter. Signaturefd LLC increased its stake in Cullinan Therapeutics by 689.7% in the 4th quarter. Signaturefd LLC now owns 4,130 shares of the company’s stock valued at $43,000 after buying an additional 3,607 shares during the last quarter. SG Americas Securities LLC bought a new stake in Cullinan Therapeutics during the third quarter worth $62,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Cullinan Therapeutics by 44.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock worth $62,000 after buying an additional 2,523 shares during the last quarter. 86.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on CGEM shares. Morgan Stanley reiterated an “overweight” rating and issued a $30.00 price objective on shares of Cullinan Therapeutics in a research report on Thursday, January 8th. Wedbush increased their price target on Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cullinan Therapeutics in a research report on Monday, December 29th. Wall Street Zen downgraded Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Finally, Citigroup assumed coverage on Cullinan Therapeutics in a report on Tuesday, February 17th. They issued a “buy” rating and a $33.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.33.

More Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

• Neutral Sentiment: Recent short-interest data for CGEM appears unreliable (reports show 0 shares and NaN change), so there’s no clear evidence of rising short interest to explain price moves — treat that data as a likely reporting glitch.
• Neutral Sentiment: Broader market weakness (e.g., a sharp pullback in Bitcoin this month) can contribute to risk-off flows in small-cap and biotech stocks, but this is an indirect factor. Bitcoin article
• Negative Sentiment: Multiple insiders sold shares on Feb. 24 — combined ~27,051 shares (~$390.6k at ~ $14.47 average). CEO Nadim Ahmed sold 13,515 shares (≈$195.6k), reducing his stake by ~3.34%. These sizable, contemporaneous sales by the CEO and other executives can be perceived negatively by the market as signal of insider profit-taking or reduced conviction. SEC filings: Ahmed filing, Sumer filing, Jones filing, Michaelson filings

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.